← Back to patent-cliff list
盐酸羟甲唑啉
Tier C — Watch / tradeOxymetazoline Hydrochloride
-
Originator
1964
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：ADRA1A
Brand：Nasivin、Rhinofrenol、Nasivine、Iliadin、Oxilin、Sinerol、Nezeril、Rhofade、Afrin、Rhinolitan、Afrazine、Hazol、Nesivine、Nafrine
Indications (approved)：鼻塞、充血
Regional status
US
临床二期
2012-12-01
EU
无进展
2014-11-01
China
批准上市
1992-01-01
Japan
批准上市
2007-08-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Oxymetazoline Hydrochloride?
Approved indications include: 鼻塞, 充血.
When does the Oxymetazoline Hydrochloride patent expire?
No public expiry year is available for Oxymetazoline Hydrochloride yet; this page updates once verified.
How do I get a quote for Oxymetazoline Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25